Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") is underway and the first dosing visit for all nine study participants has already concluded. The Study is a three-arm, crossover investigation that will compare three 7 mg semaglutide dose formulations: a positive control Rybelsus® swallowed tablet (already dosed); DehydraTECH-semaglutide swallowed capsules; and for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. The second DehydraTECH Study arm will use a Rybelsus® composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration's Inactive Ingredient Database ("FDA IID"), delivered within swallowed capsules. The dosing interval for this Study arm is currently anticipated to complete during mid-June, after the necessary wash-out period for the study participants from the first Study arm. The acidic environment of the stomach seriously degrades GLP-1 drugs that are swa
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy [Yahoo! Finance]Yahoo! Finance
- Lexaria Receives Two New Medical-Treatment Patents in Hypertension and EpilepsyAccesswire
- Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study [Yahoo! Finance]Yahoo! Finance
- Dosing Begins in Lexaria's Comprehensive GLP-1 Animal StudyAccesswire
- Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
LEXX
Analyst Actions
- 3/5/24 - Maxim Group
LEXX
Sec Filings
- 5/15/24 - Form 4
- 5/10/24 - Form 4
- 5/10/24 - Form 4
- LEXX's page on the SEC website